Component

Plasma simvastatin exposure

Plasma simvastatin exposure. Species, exposure and limitations are retained in each linked claim.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The investigators concluded that the increased risk of myopathy during combined simvastatin and gemfibrozil treatment is at least partially of pharmacokinetic origin.

    Plasma simvastatin exposure → Statin-associated muscle pain source_derived_draftungraded
    Experimental context and source evidence
    duration
    3 days
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    10 healthy volunteers, with the myopathy association drawn from prior case reports
    exposure
    Gemfibrozil co-treatment raising simvastatin acid exposure by 185 percent
    limitations
    This is the authors' mechanistic conclusion linking their measured exposure change to a myopathy risk reported elsewhere, not a measurement of muscle injury in these ten volunteers.
    organism
    10 healthy volunteers, with the myopathy association drawn from prior case reports
    plain_language
    The investigators concluded that the increased risk of myopathy during combined simvastatin and gemfibrozil treatment is at least partially of pharmacokinetic origin.
    primary_references
    Plasma concentrations of active simvastatin acid are increased by gemfibrozil. (2000). https://pubmed.ncbi.nlm.nih.gov/10976543/ DOI: 10.1067/mcp.2000.108507
    route
    Oral
    tissue
    Plasma simvastatin acid concentration and muscle injury risk

    Statin plasma exposure and muscle injury: dose randomisation and a drug interaction (2026-09-22) · lines 35–44

    Original AI-assisted curation of three primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Two share a research group with the OATP1B1 collection and are recorded as one line of evidence with it. Study-specific doses, effect sizes and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## simvastatin-exposure-raises-myopathy The investigators concluded that the increased risk of myopathy during combined simvastatin and gemfibrozil treatment is at least partially of pharmacokinetic origin. Model/species: 10 healthy volunteers, with the myopathy association drawn from prior case reports Tissue/system: Plasma simvastatin acid concentration and muscle injury risk Exposure: Gemfibrozil co-treatment raising simvastatin acid exposure by 185 percent Route: Oral Duration: 3 days Limits: This is the authors' mechanistic conclusion linking their measured exposure change to a myopathy risk reported elsewhere, not a measurement of muscle injury in these ten volunteers. Primary reference: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. (2000). https://pubmed.ncbi.nlm.nih.gov/10976543/ DOI: 10.1067/mcp.2000.108507 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

What acts on it

  1. Gemfibrozil increased the plasma exposure of active simvastatin acid by 185 percent and its peak concentration by 112 percent.

    Gemfibrozil → Plasma simvastatin exposure source_derived_draftungraded
    Experimental context and source evidence
    duration
    3 days of gemfibrozil, 12 hours of sampling
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    10 healthy volunteers, double-blind randomised crossover
    exposure
    Gemfibrozil 600 mg twice daily for 3 days, then a single 40 mg simvastatin dose
    limitations
    Gemfibrozil did not inhibit CYP3A4 in human liver microsomes, so the interaction is not a CYP3A4 effect; the authors attribute it to inhibition of non-CYP3A4 metabolism of simvastatin acid.
    organism
    10 healthy volunteers, double-blind randomised crossover
    plain_language
    Gemfibrozil increased the plasma exposure of active simvastatin acid by 185 percent and its peak concentration by 112 percent.
    primary_references
    Plasma concentrations of active simvastatin acid are increased by gemfibrozil. (2000). https://pubmed.ncbi.nlm.nih.gov/10976543/ DOI: 10.1067/mcp.2000.108507
    route
    Oral
    tissue
    Plasma simvastatin lactone and active simvastatin acid

    Statin plasma exposure and muscle injury: dose randomisation and a drug interaction (2026-09-22) · lines 24–33

    Original AI-assisted curation of three primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Two share a research group with the OATP1B1 collection and are recorded as one line of evidence with it. Study-specific doses, effect sizes and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## gemfibrozil-raises-simvastatin-acid-exposure Gemfibrozil increased the plasma exposure of active simvastatin acid by 185 percent and its peak concentration by 112 percent. Model/species: 10 healthy volunteers, double-blind randomised crossover Tissue/system: Plasma simvastatin lactone and active simvastatin acid Exposure: Gemfibrozil 600 mg twice daily for 3 days, then a single 40 mg simvastatin dose Route: Oral Duration: 3 days of gemfibrozil, 12 hours of sampling Limits: Gemfibrozil did not inhibit CYP3A4 in human liver microsomes, so the interaction is not a CYP3A4 effect; the authors attribute it to inhibition of non-CYP3A4 metabolism of simvastatin acid. Primary reference: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. (2000). https://pubmed.ncbi.nlm.nih.gov/10976543/ DOI: 10.1067/mcp.2000.108507 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  2. No clinically obvious pharmacokinetic interaction with simvastatin was detected in the tested berberine-chloride combination regimen.

    Berberine → Plasma simvastatin exposure source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/berberine-research/30587933.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f82b466cc2942fd70940935e1fa42174f135036017a589bc7fa86388e6f9e4be", "start_char": 0, "end_char": 2118, "text_sha256": "f82b466cc2942fd70940935e1fa42174f135036017a589bc7fa86388e6f9e4be"}
    experimental_model
    Open-label randomized parallel pharmacokinetic study
    exposure
    Single-dose and seven-day repeated treatment; berberine chloride alone or combined
    limitations
    Short, small healthy-volunteer study. Absence of an obvious interaction here does not establish unrestricted long-term safety in patients.
    nutrient_topic
    Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
    organism
    Sixty healthy Chinese participants across five groups
    plain_language
    The measured result limits a blanket claim that every relevant drug concentration must rise.
    primary_references
    [berberine-p30587933] Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects. (2019). https://pubmed.ncbi.nlm.nih.gov/30587933/ DOI: 10.2147/dddt.s185487
    tissue_or_cell_type
    Simvastatin and fenofibrate exposure

    Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 935–946

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Open-label randomized parallel pharmacokinetic study · source_derived_draft · unverified_draft

    ### berberine-clinical-statin-null No clinically obvious pharmacokinetic interaction with simvastatin was detected in the tested berberine-chloride combination regimen. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: The measured result limits a blanket claim that every relevant drug concentration must rise. organism: Sixty healthy Chinese participants across five groups tissue_or_cell_type: Simvastatin and fenofibrate exposure experimental_model: Open-label randomized parallel pharmacokinetic study limitations: Short, small healthy-volunteer study. Absence of an obvious interaction here does not establish unrestricted long-term safety in patients. exposure: Single-dose and seven-day repeated treatment; berberine chloride alone or combined evidence_span: {"source_cache": "artifacts/berberine-research/30587933.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f82b466cc2942fd70940935e1fa42174f135036017a589bc7fa86388e6f9e4be", "start_char": 0, "end_char": 2118, "text_sha256": "f82b466cc2942fd70940935e1fa42174f135036017a589bc7fa86388e6f9e4be"} [berberine-p30587933] Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects. (2019). https://pubmed.ncbi.nlm.nih.gov/30587933/ DOI: 10.2147/dddt.s185487
    Complete structured claim and evidence

  3. Volunteers with the SLCO1B1 c.521CC genotype had 221 percent greater plasma exposure to active simvastatin acid than those with the c.521TT genotype.

    SLCO1B1 c.521T>C reduced-function variant → Plasma simvastatin exposure source_derived_draftungraded
    Experimental context and source evidence
    duration
    Single dose with 12-hour sampling
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    4 volunteers with c.521CC, 12 with c.521TC and 16 with c.521TT
    exposure
    Single 40 mg oral simvastatin dose
    limitations
    Peak concentration was 200 percent higher and occurred earlier in c.521CC carriers; the four-carrier group is small.
    organism
    4 volunteers with c.521CC, 12 with c.521TC and 16 with c.521TT
    plain_language
    Volunteers with the SLCO1B1 c.521CC genotype had 221 percent greater plasma exposure to active simvastatin acid than those with the c.521TT genotype.
    primary_references
    SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. (2006). https://pubmed.ncbi.nlm.nih.gov/17108811/ DOI: 10.1097/01.fpc.0000230416.82349.90
    route
    Oral
    tissue
    Plasma simvastatin lactone and active simvastatin acid

    OATP1B1 activity and statin exposure: the step between transporter inhibition and drug concentration (2026-09-22) · lines 57–66

    Original AI-assisted curation of four primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Three of the four share one research group and are recorded as one line of evidence. Study-specific citations, doses and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## slco1b1-c521cc-raises-simvastatin-acid-exposure Volunteers with the SLCO1B1 c.521CC genotype had 221 percent greater plasma exposure to active simvastatin acid than those with the c.521TT genotype. Model/species: 4 volunteers with c.521CC, 12 with c.521TC and 16 with c.521TT Tissue/system: Plasma simvastatin lactone and active simvastatin acid Exposure: Single 40 mg oral simvastatin dose Route: Oral Duration: Single dose with 12-hour sampling Limits: Peak concentration was 200 percent higher and occurred earlier in c.521CC carriers; the four-carrier group is small. Primary reference: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. (2006). https://pubmed.ncbi.nlm.nih.gov/17108811/ DOI: 10.1097/01.fpc.0000230416.82349.90 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards